Q-omics provides the consensus-scored TRBV12-3 profile across patient tissues and cancer cell-line models. TRBV12-3 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TRBV12-3 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, TRBV12-3 RNA expression shows 13,829 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, KIRC, and TGCT as cancer lineages where TRBV12-3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRBV12-3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRBV12-3 survival associations across molecular data types. TRBV12-3 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRBV12-3 RNA expression–survival associations across cancer types. High TRBV12-3 expression shows unfavorable associations in UVM, but favorable associations in HNSC, UCEC, SKCM, CESC and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TRBV12-3 RNA expression.
This table summarizes TRBV12-3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRBV12-3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRBV12-3 shows lower tumor expression in COAD and higher tumor expression in KIRC, BRCA, ESCA, STAD and LUAD. The KIRC box plot shows higher TRBV12-3 RNA expression in tumor versus normal tissue (log2 FC = +1.102, t-test p < 0.001).
This table shows molecular features associated with TRBV12-3 in patient tissues and cancer cell lines. In patient samples, TRBV12-3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
